𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Characterization of a 90-100 kDa tumor-associated antigen in the sera of melanoma patients

✍ Scribed by David M. Euhus; Rishab K. Gupta; Donald L. Morton

Publisher
John Wiley and Sons
Year
1990
Tongue
French
Weight
694 KB
Volume
45
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Using allogeneic antibody, we previously described a highmolecular‐weight glycoprotein in the urine of 68% of melanoma patients. This glycoprotein has been termed urinarytumor‐associated antigen (U‐TAA). A murine monoclonal antibody (MAb) specific for U‐TAA (AD1‐40F4) has been developed. By the use of AD1‐40F4, U‐TAA was detected in serum samples from 63% (33/52) of stage II and stage III melanoma patients, but from only 5% (1/20) of normal controls. This report describes the physical and immunochemical properties of U‐TAA in the serum. The antigen elutes from a DEAE‐Sephacel column in association with IgG in the void volume and as free antigen in a second peak. The molecular mass of the free antigen is 590–620 kDa and it sediments in the region of 28–29% sucrose by density gradient ultracentrifugation. Free antigen has an isoelectric point of 6.1. This high molecular weight antigen is composed of smaller subunits linked by reducible bonds. The AD1‐40F4 reactive epitope resides on a 90–100 kDa subunit. These results provide evidence that U‐TAA which is produced by melanoma cells in vitro is present in the circulation of melanoma patients.

📜 SIMILAR VOLUMES

Determination of incidence and partial c
Determination of incidence and partial characterization of tumor-associated antigens found in the urine of patients bearing solid tumors
✍ N. S. Rote; R. K. Gupta; D. L. Morton 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 French ⚖ 739 KB

## Abstract Urine samples from patients with solid tumors and from donors without malignant disease were concentrated and tested for the presence of tumor‐associated antigens. In the complement‐fixation assay using serum from a source autologous with the source of the urine, 87.4% of cancer patient

Detection of a tumor-associated glycopro
Detection of a tumor-associated glycoprotein antigen in serum and urine of melanoma patients by murine monoclonal antibody (AD1-40F4) in enzyme immunoassay
✍ David M. Euhus; Ph.D. Rishab K. Gupta; Donald L. Morton 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 620 KB

The urine of 68% of melanoma patients contains a high molecular weight glycoprotein which is expressed by melanoma cells and reacts with autologous antibody. Since high levels of this antigen in urine correlate with disease recurrence in surgically treated melanoma patients, it has been termed urina

Recombinant alpha-2b-interferon enhances
Recombinant alpha-2b-interferon enhances the circulating levels of a 90-kilodalton (K) tumor-associated antigen in patients with gynecologic and breast malignancies
✍ Giovanni Scambia; Pierluigi Benedetti Panici; Stefano Iacobelli; Gabriela Baiocc 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 372 KB 👁 3 views

The circulating levels of a 90-kilodalton (K) tumor-associated antigen were measured in the blood of 43 patients with gynecologic and breast malignancies who underwent a short course of recombinant alpha-2b-interferon (rIFN a-zb) (3 million U/m2/d intramuscularly [IM] for 3 days). Of the 43 patients

Favorable outcome in clinically stage II
Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression
✍ Inge S. van Houdt; Berbel J.R. Sluijter; Laura M. Moesbergen; Wim M. Vos; Tanja 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 296 KB 👁 1 views

## Abstract In this study we investigated whether the presence of specific populations of tumor infiltrating lymphocytes (TILs) in diagnostic primary melanoma biopsies are related to outcome in clinically stage II melanoma patients. Moreover, we investigated whether the presence of TILs correlates

Specific active immunotherapy in patient
Specific active immunotherapy in patients with adenocarcinoma of the colon utilizing tumor-associated antigens (TAA). A phase I clinical trial
✍ Ariel Hollinshead; E. George Elias; Myron Arlen; Barbara Buda; Maria Mosley; Jos 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 838 KB

Twenty-two patients received specific active immunotherapy (TAA vaccine once per month for 3 months), with the duration of follow-up, as of July 1984, ranging from 3 months to 36 months (median, 21 months). Of these, seven had Dukes Bz, seven had Dukes C, and eight had Dukes D lesions. All received